Establishment Labs Holdings Inc (ESTA)

$45.47

-0.97

(-2.09%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $44.33
    $47.13
    $45.47
    downward going graph

    2.51%

    Downside

    Day's Volatility :5.94%

    Upside

    3.52%

    downward going graph
  • $16.96
    $73.00
    $45.47
    downward going graph

    62.7%

    Downside

    52 Weeks Volatility :76.77%

    Upside

    37.71%

    downward going graph

Returns

PeriodEstablishment Labs Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
-5.8%
6.4%
0.0%
6 Months
21.03%
6.0%
0.0%
1 Year
-33.94%
9.6%
0.0%
3 Years
-37.71%
14.8%
-19.4%

Highlights

Market Capitalization
1.3B
Book Value
$2.07
Earnings Per Share (EPS)
-3.17
Wall Street Target Price
65.0
Profit Margin
-53.12%
Operating Margin TTM
-23.77%
Return On Assets TTM
-16.07%
Return On Equity TTM
-404.56%
Revenue TTM
155.8M
Revenue Per Share TTM
5.91
Quarterly Revenue Growth YOY
-20.1%
Gross Profit TTM
106.6M
EBITDA
-61.2M
Diluted Eps TTM
-3.17
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.81
EPS Estimate Next Year
-0.79
EPS Estimate Current Quarter
-0.67
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Establishment Labs Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 42.95%

Current $45.47
Target $65.00

Company Financials

FY18Y/Y Change
Revenue
61.2M
↑ 76.49%
Net Income
-21.1M
↓ 39.54%
Net Profit Margin
-34.47%
↑ 66.15%
FY19Y/Y Change
Revenue
89.6M
↑ 46.33%
Net Income
-38.2M
↑ 80.82%
Net Profit Margin
-42.59%
↓ 8.12%
FY20Y/Y Change
Revenue
84.7M
↓ 5.46%
Net Income
-38.1M
↓ 0.08%
Net Profit Margin
-45.02%
↓ 2.43%
FY21Y/Y Change
Revenue
126.7M
↑ 49.61%
Net Income
-41.1M
↑ 7.92%
Net Profit Margin
-32.47%
↑ 12.55%
FY22Y/Y Change
Revenue
161.7M
↑ 27.64%
Net Income
-75.2M
↑ 82.82%
Net Profit Margin
-46.51%
↓ 14.04%
FY23Y/Y Change
Revenue
165.2M
↑ 2.13%
Net Income
-78.5M
↑ 4.38%
Net Profit Margin
-47.53%
↓ 1.02%
Q4 FY22Q/Q Change
Revenue
43.8M
↑ 14.56%
Net Income
-13.6M
↓ 27.12%
Net Profit Margin
-30.95%
↑ 17.7%
Q1 FY23Q/Q Change
Revenue
46.5M
↑ 6.19%
Net Income
-11.9M
↓ 11.95%
Net Profit Margin
-25.67%
↑ 5.28%
Q2 FY23Q/Q Change
Revenue
48.6M
↑ 4.38%
Net Income
-16.7M
↑ 40.22%
Net Profit Margin
-34.48%
↓ 8.81%
Q3 FY23Q/Q Change
Revenue
38.5M
↓ 20.71%
Net Income
-29.3M
↑ 74.82%
Net Profit Margin
-76.02%
↓ 41.54%
Q4 FY23Q/Q Change
Revenue
31.6M
↓ 18.04%
Net Income
-20.5M
↓ 29.83%
Net Profit Margin
-65.09%
↑ 10.93%
Q1 FY24Q/Q Change
Revenue
37.2M
↑ 17.77%
Net Income
-16.2M
↓ 21.13%
Net Profit Margin
-43.59%
↑ 21.5%
FY18Y/Y Change
Total Assets
116.6M
↑ 104.17%
Total Liabilities
47.1M
↓ 24.18%
FY19Y/Y Change
Total Assets
116.5M
↓ 0.04%
Total Liabilities
76.9M
↑ 63.35%
FY20Y/Y Change
Total Assets
156.4M
↑ 34.2%
Total Liabilities
81.4M
↑ 5.86%
FY21Y/Y Change
Total Assets
139.5M
↓ 10.78%
Total Liabilities
88.8M
↑ 9.04%
FY22Y/Y Change
Total Assets
211.1M
↑ 51.27%
Total Liabilities
219.2M
↑ 146.93%
FY23Y/Y Change
Total Assets
268.6M
↑ 27.28%
Total Liabilities
250.2M
↑ 14.14%
Q4 FY22Q/Q Change
Total Assets
211.1M
↑ 12.47%
Total Liabilities
219.2M
↑ 17.79%
Q1 FY23Q/Q Change
Total Assets
209.4M
↓ 0.81%
Total Liabilities
225.4M
↑ 2.79%
Q2 FY23Q/Q Change
Total Assets
285.3M
↑ 36.27%
Total Liabilities
230.4M
↑ 2.25%
Q3 FY23Q/Q Change
Total Assets
270.5M
↓ 5.18%
Total Liabilities
240.0M
↑ 4.17%
Q4 FY23Q/Q Change
Total Assets
268.6M
↓ 0.7%
Total Liabilities
250.2M
↑ 4.25%
Q1 FY24Q/Q Change
Total Assets
301.8M
↑ 12.36%
Total Liabilities
244.9M
↓ 2.13%
FY18Y/Y Change
Operating Cash Flow
-33.9M
↑ 5.99%
Investing Cash Flow
-5.7M
↑ 578.22%
Financing Cash Flow
81.5M
↑ 89.63%
FY19Y/Y Change
Operating Cash Flow
-30.0M
↓ 11.52%
Investing Cash Flow
-7.8M
↑ 35.51%
Financing Cash Flow
22.8M
↓ 72.05%
FY20Y/Y Change
Operating Cash Flow
-12.5M
↓ 58.28%
Investing Cash Flow
-5.6M
↓ 28.42%
Financing Cash Flow
64.7M
↑ 183.78%
FY21Y/Y Change
Operating Cash Flow
-27.5M
↑ 120.08%
Investing Cash Flow
-7.2M
↑ 28.85%
Financing Cash Flow
4.1M
↓ 93.73%
FY22Y/Y Change
Operating Cash Flow
-52.2M
↑ 89.47%
Investing Cash Flow
-34.8M
↑ 385.7%
Financing Cash Flow
100.3M
↑ 2374.21%
Q4 FY22Q/Q Change
Operating Cash Flow
-14.0M
↓ 36.23%
Investing Cash Flow
-10.4M
↑ 116.8%
Financing Cash Flow
25.0M
↑ 1874.47%
Q1 FY23Q/Q Change
Operating Cash Flow
-20.6M
↑ 47.07%
Investing Cash Flow
-4.3M
↓ 58.98%
Financing Cash Flow
1.2M
↓ 95.26%
Q2 FY23Q/Q Change
Operating Cash Flow
-28.2M
↑ 36.99%
Investing Cash Flow
-9.0M
↑ 111.52%
Financing Cash Flow
84.5M
↑ 7042.18%

Technicals Summary

Sell

Neutral

Buy

Establishment Labs Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc
6.41%
21.03%
-33.94%
-37.71%
96.33%
Stryker Corporation
Stryker Corporation
-0.12%
8.84%
15.17%
33.61%
63.53%
Boston Scientific Corp.
Boston Scientific Corp.
0.73%
27.69%
45.08%
81.26%
82.49%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-2.63%
15.09%
-6.64%
-18.84%
33.76%
Abbott Laboratories
Abbott Laboratories
-4.26%
-10.65%
-8.76%
-14.07%
15.85%
Medtronic Plc
Medtronic Plc
-0.86%
-8.08%
-11.05%
-36.67%
-21.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc
NA
NA
NA
-1.81
-4.05
-0.16
NA
2.07
Stryker Corporation
Stryker Corporation
37.9
37.9
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.49
63.49
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.97
36.97
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.57
31.57
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.42
29.42
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc
Buy
$1.3B
96.33%
NA
-53.12%
Stryker Corporation
Stryker Corporation
Buy
$126.2B
63.53%
37.9
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
82.49%
63.49
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.1B
33.76%
36.97
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$174.1B
15.85%
31.57
13.96%
Medtronic Plc
Medtronic Plc
Buy
$104.1B
-21.49%
29.42
11.36%

Insights on Establishment Labs Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 31.56M → 37.16M (in $), with an average increase of 15.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -29.27M → -16.20M (in $), with an average increase of 34.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 45.1% return, outperforming this stock by 79.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 81.3% return, outperforming this stock by 119.0%

Institutional Holdings

  • JW Asset Management, LLC

    11.60%
  • RTW INVESTMENTS, LLC

    9.72%
  • Brown Advisory Holdings Inc

    8.43%
  • Nantahala Capital Management, LLC

    7.14%
  • JPMorgan Chase & Co

    3.45%
  • COWEN AND COMPANY, LLC

    3.42%

Company Information

establishment labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. with more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for establishment labs’ founders and top executives. as a result, motiva implants® has established a level of product innovation that always results in safety. and while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. we believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.

Organization
Establishment Labs Holdings Inc
Employees
908
CEO
Mr. Juan Jose Chacon Quiros
Industry
Health Technology

FAQs